PTC Therapeutics (PTCT) Given News Sentiment Rating of 0.10

Headlines about PTC Therapeutics (NASDAQ:PTCT) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. PTC Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.1444456475761 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news articles that may have impacted Accern’s rankings:

PTC Therapeutics (NASDAQ:PTCT) traded up 6.77% during trading on Friday, hitting $17.35. 556,371 shares of the company traded hands. PTC Therapeutics has a 12-month low of $4.03 and a 12-month high of $22.00. The stock has a 50-day moving average price of $18.93 and a 200-day moving average price of $16.98. The firm’s market capitalization is $718.10 million.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.89) by $0.45. The firm had revenue of $47.96 million during the quarter, compared to analysts’ expectations of $28.78 million. PTC Therapeutics had a negative return on equity of 81.84% and a negative net margin of 88.43%. The company’s revenue was up 206.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.14) earnings per share. Equities analysts expect that PTC Therapeutics will post ($2.35) EPS for the current fiscal year.

PTCT has been the subject of a number of recent research reports. Bank of America Corporation cut shares of PTC Therapeutics from a “neutral” rating to an “underperform” rating in a research note on Thursday. BidaskClub lowered shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. Barclays PLC reduced their target price on shares of PTC Therapeutics from $22.00 to $15.00 and set an “equal weight” rating on the stock in a research note on Friday, September 29th. William Blair initiated coverage on shares of PTC Therapeutics in a research note on Wednesday, August 23rd. They issued a “market perform” rating and a $17.00 target price on the stock. Finally, Cowen and Company reaffirmed a “hold” rating on shares of PTC Therapeutics in a research note on Wednesday. Three analysts have rated the stock with a sell rating, eight have given a hold rating and two have issued a buy rating to the stock. PTC Therapeutics currently has an average rating of “Hold” and an average price target of $17.44.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Insider Buying and Selling by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply